Press Release
atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m.
August 9, 2021
Press Release
atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in a fireside chat and one-on-one investor meetings at the
August 6, 2021
Press Release
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest , Australia’s leading university technology transfer
July 28, 2021
Press Release
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in
July 7, 2021
Press Release
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000
June 17, 2021
Press Release
atai Life Sciences Announces Launch of Initial Public Offering
BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V.(“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common
June 11, 2021
Displaying 79 - 84 of 107